Nature Immunology, Published online: 03 February 2026; doi:10.1038/s41590-025-02409-y
The identification of a new Asn332 glycan-independent anti-HIV-1 neutralizing antibody that targets the V3 epitope, together with an Asn332 glycan-deficient priming immunogen capable of inducing B cell precursors of Asn332 glycan-dependent and -independent neutralizing antibodies, redefines the V3 loop in HIV-1 vaccine development.
Read more about this post…
Credits: Source
Disclaimer




Serving